Specifically, our observation that EYA4 is hypermethylated in the first intron–exon junction particularly in triple-negative breast cancer patients when compared to matched normal samples, led us to pursue its role in carcinogenesis and its cellular functions. Here, EYA4 is linked to triple-negative breast carcinoma.